(A) A single nucleotide polymorphism (SNP) is a frequent (>1%) genomic variant at a single base position in the DNA. Some SNPs in the coding region of a gene (exon) change the amino acid sequence of a protein, and others in the coding region do not affect the protein sequence. 

(B) Polygenic risk scores (PRS) are typically calculated by summing the weighted allele counts of independent (i.e., uncorrelated) SNPs found to be associated with a trait or disorder in a genome-wide association study (GWAS). For quantitative traits, the weights are the linear regression effect sizes, i.e., the β coefficients. The weights for case/control phenotypes are the natural logarithm of the odds ratio, ln(OR).

(C ) Polygenic risk scores (PRS) follow a normal distribution on a population level. The distributions of cases and controls clearly overlap. Thus, meaningful risk predictions can be only expected for extreme quantiles at the top and bottom of the PRS distributions.

file_download Download in HQ

Related content

description Article
Treatment-Resistant Depression (TRD) – definition, clinical manifestation, and evidence-based treatment

Treatment-resistant depression (TRD) represents a significant clinical challenge, affecting approximately 30% of individuals with major depressive disorder (MDD) who fail to respond to at least two adequate antidepressant trials.

25.09.2025 Depression
image Image Diagram titled 'Sequential Treatment Optimization Scheme for MDD' showing patient improvement over treatment time across four stages. Stage 1 includes monotherapy, dose optimization, and rTMS; Stage 2 includes augmentation, combination antidepressant, add-on treatment, rTMS/ECT; Stage 3 includes add-on psychopharmacotherapy, switch to tranylcypromine, rTMS/TBS/ECT/VNS; Stage 4 includes repetition or experimental psychopharmacotherapy/brain stimulation. Curved lines represent different patient trajectories, with horizontal dotted lines indicating thresholds for response and remission. Some lines show improvement, while others show little or worsening response over time.
Sequental Treatment Optimization Scheme for Major Depressive Disorder

Sequential treatment optimization scheme for major depressive disorder generated according to international evidence.

18.09.2025 Depression
image Image Infographic titled 'Identification and Effective Management of Factors Potentially Confounding Treatment Response'. It shows eight stacked boxes listing key steps: Check dose and duration of the current antidepressant trial Explore and reduce side effects Consider and treat comorbidities Consider and reduce ongoing stressors Evaluate treatment adherence Pharmacogenomic testing (CYP450) Check and avoid unfavorable medical interaction Evaluate initial therapies and follow recommended treatment algorithm. At the bottom, references are cited (Dold & Kasper, 2017; Kraus et al., 2019), and the image is credited to Neurotorium."
Identification and effective management of factors potentially confounding treatment response

Key steps for managing factors that may confound antidepressant treatment response, including dose, side effects, comorbidities, stressors, adherence, pharmacogenomics, interactions, and treatment algorithms.

18.09.2025 Depression